LBA56 - Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL

Autor:	Eisen, T.Q.G. 1, Frangou, E. 2, Smith, B. 2, Ritchie, A. 2, Kaplan, R.S. 2, Oza, B. 2, Davis, I.D. 3, Stockler, M.R. 4, Albiges, L. 5, Escudier, B. 5, Larkin, J.M.G. 6, Bex, A. 7, Joniau, S. 8, Hancock, B.W. 9, Hermann, G.G. 10, Bellmunt, J. 11, Hodgkinson, E. 12, Hanlon, P. 2, Parmar, M.K.B. 2, Meade, A.M. 2
Zdroj:	In Annals of Oncology October 2019 30 Supplement 5:v891-v892
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu